Drug intelligence / Profile preview

Bronchodual

Development stage: Preclinical
Modality: Small Molecules
Administration: Inhalation

Overview

Bronchodual is a combination pharmaceutical drug administered via metered aerosol, consisting of two bronchodilators: fenoterol (a beta-2 adrenergic substance) and ipratropium bromide (an anticholinergic substance). It is primarily used for the long-term treatment of asthma in children and adults. The combination provides a bronchodilating action superior to that of each substance individually, allowing for a reduced dose of the beta-2 adrenergic component, a longer duration of action, and a decrease in the frequency of drug intake, with excellent tolerance.

Brand names: Bronchodual

Targets

CHRM2 (M2)M1 (Muscarinic acetylcholine receptor M1)CHRM3 (M3)ADRB2 (β2)

Beyond the preview

Go deeper on Bronchodual.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bronchodual.

Explore the full profile